A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer

Thyroid

Volumn 24, Issue 10, 2014, Pages 1508-1514

  Cabanillas, Maria E ^a   Brose, Marcia S ^b   Holland, Jaymes ^c   Ferguson, Kimberly C ^c   Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CABOZANTINIB; CALCIUM; CREATINE KINASE; CYTOKINE RECEPTOR ANTAGONIST; HEMOGLOBIN; LACTATE DEHYDROGENASE; PHOSPHORUS; RADIOACTIVE IODINE; ROSIGLITAZONE; SORAFENIB; TRIACYLGLYCEROL LIPASE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANILIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; BACKACHE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; NAUSEA; NECK PAIN; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SINGLE DRUG DOSE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; TREATMENT RESPONSE; VITAL SIGN; WEIGHT REDUCTION; CARCINOMA; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENZYMOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SECONDARY; THYROID NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 84911888284     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0125     Document Type: Article

References (35)

1. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH 2011 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308
2. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R 2011 Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666
3. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M 2013 Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419
4. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EEW, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI 2013 Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31: 3639-3646
5. Menicali E, Moretti S, Voce P, Romagnoli S, Avenia N, Puxeddu E 2012 Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) 3:67
6. Mineo R, Costantino A, Frasca F, Sciacca L, Russo S, Vigneri R, Belfiore A 2004 Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 145:4355-4365
7. Cassinelli G, Favini E, DeglInnocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C 2009 RET/ PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11:10-21
8. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976
9. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552-558
10. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K 2008 Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 40:210-213
11. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger, MJ, on behalf of the DECISION investigators 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319-328
12. Keefe SM, Cohen MA, Brose MS 2010 Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 16:778-783
13. Haugen BR, Sherman SI 2013 Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 34:439-455
14. Dadu R, Cabanillas ME 2012 Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol 37:335-356
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
16. Dadu R, Devine C, Hernandez M, Waquespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME 2014 Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99:2086-2094
17. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
18. Cabanillas ME, Hu MI, Durand JB, Busaidy NL 2011 Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011: 985780
19. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134-141
20. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME 2014 Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24:918-922
21. Kamba T, McDonald DM 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795
22. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME 2014 Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19:251-258
23. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newvold K, Dlisei R, OBrien JP, Schlumberger M 2011 A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 29 (suppl; abstr 5503
24. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris III JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C for the Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and The Mayo Phase 2 Consortium. 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
25. Coleman RE 2006 Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s-6249s.
26. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931
27. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595
28. Aftab DT, McDonald DM 2011 MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 13:703-709
29. Schimmoller F, Zayzafoon M, Chung LWK, Zhau HE, Fagerlund KM, Aftab DT 2011 Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol Cancer Ther 10:233 (suppl 1; abstr A233
30. Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, Schimmoller F, Keller ET 2014 Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 20:617-630
31. Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E 2013 Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 8:e78881
32. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI 2014 Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II non-randomized expansion study. J Clin Oncol 32 (In press
33. Tolaney SM, Nechushtan H, Berger R, Kurzrock R, Ron I, Schöffski P, Awada A, Yasenchak C, Burris H, Ramies D, Shen X, Winer E 2011 Cabozantinib (XL184) in patients with metastatic breast cancer: results from a phase 2 randomized discontinuation trial. Cancer Res 71:243s (suppl 3; abstr P1-17-10
34. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR 2013 A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 19: 3088-3094
35. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens PJ, Ross J, Miller VA, Ginsberg MS, Zakowski MF, Kris MG, Ladanyi M, Rizvi NA 2013 Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630-635